PRIMARY PURPOSE: The objective of this retrospective observational cohort study was to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in patients with chemotherapy-induced anemia using data from noncontemporaneous chart audits conducted at a community-based oncology practice. MATERIALS AND METHODS: For the first chart audit, data were collected from consecutive patients with nonmyeloid malignancies with diagnoses of chemotherapy-induced anemia and hemoglobin levels < or = 10.5 g/dl who were receiving concurrent chemotherapy and had at least 5 weeks of visits from July-September 2000. After therapeutic substitution of darbepoetin alfa for epoetin alfa for all patients with chemotherapy-induced anemia, data were collected from consecutive darbepoetin alfa-treated patients with diagnoses of chemotherapy-induced anemia and at least 8 weeks of visits from June-October 2002 (darbepoetin alfa was approved in July 2002). RESULTS: Most (86%) of the 212 epoetin alfa-treated patients had received an initial dose of 40,000 U once weekly, and most (85%) of the 196 darbepoetin alfa-treated patients had received a fixed dose of either 100 microg once weekly (49%) or 200 microg every 2 weeks (36%). At 8 weeks, the mean change in hemoglobin level was 1.1 g/dl for the darbepoetin alfa patient group and 1.0 g/dl for the epoetin alfa patient group. DISCUSSION: Utilization, dose escalation rates, and clinical outcomes were considered comparable for the darbepoetin alfa and epoetin alfa patient groups. CONCLUSIONS: Darbepoetin alfa, 100 microg once weekly or 200 microg every 2 weeks, appears to be as effective as epoetin alfa, 40,000 U once weekly, for the treatment of chemotherapy-induced anemia in the clinical practice setting. Copyright AlphaMed Press
PRIMARY PURPOSE: The objective of this retrospective observational cohort study was to compare the effectiveness of darbepoetin alfa with that of epoetinalfa in patients with chemotherapy-induced anemia using data from noncontemporaneous chart audits conducted at a community-based oncology practice. MATERIALS AND METHODS: For the first chart audit, data were collected from consecutive patients with nonmyeloid malignancies with diagnoses of chemotherapy-induced anemia and hemoglobin levels < or = 10.5 g/dl who were receiving concurrent chemotherapy and had at least 5 weeks of visits from July-September 2000. After therapeutic substitution of darbepoetin alfa for epoetinalfa for all patients with chemotherapy-induced anemia, data were collected from consecutive darbepoetin alfa-treated patients with diagnoses of chemotherapy-induced anemia and at least 8 weeks of visits from June-October 2002 (darbepoetin alfa was approved in July 2002). RESULTS: Most (86%) of the 212 epoetinalfa-treated patients had received an initial dose of 40,000 U once weekly, and most (85%) of the 196 darbepoetin alfa-treated patients had received a fixed dose of either 100 microg once weekly (49%) or 200 microg every 2 weeks (36%). At 8 weeks, the mean change in hemoglobin level was 1.1 g/dl for the darbepoetin alfapatient group and 1.0 g/dl for the epoetinalfapatient group. DISCUSSION: Utilization, dose escalation rates, and clinical outcomes were considered comparable for the darbepoetin alfa and epoetinalfapatient groups. CONCLUSIONS: Darbepoetin alfa, 100 microg once weekly or 200 microg every 2 weeks, appears to be as effective as epoetinalfa, 40,000 U once weekly, for the treatment of chemotherapy-induced anemia in the clinical practice setting. Copyright AlphaMed Press
Authors: Kalpesh T Vakharia; Robin W Lindsay; Christopher Knox; Colin Edwards; Doug Henstrom; Julie Weinberg; Tessa A Hadlock; James T Heaton Journal: Otolaryngol Head Neck Surg Date: 2011-01 Impact factor: 3.497
Authors: Vicente Alberola Candel; Alfredo Carrato Mena; Eduardo Díaz-Rubio García; Pere Gascón Vilaplana; Manuel González Barón; Miguel Martín Jiménez; Emilio Alba Conejo; Javier Cassinello Espinosa; Ramon Colomer; Juan Jesús Cruz Hernández; Agustí Barnadas i Molins; Carlos Camps Herrero; Ana Ma Casas Fernández de Tejerina; Joan Carulla Torrent; Manuel Constenla Figueiras; Joaquin Gavilá Gregori; Ma Dolores Isla Casado; Bartomeu Massuti Sureda; Mariano Provencio Pulla; César Augusto Rodríguez Sánchez; Jaime Sanz Ortiz Journal: Clin Transl Oncol Date: 2009-11 Impact factor: 3.405
Authors: Peter L Greenberg; Richard M Stone; Rafael Bejar; John M Bennett; Clara D Bloomfield; Uma Borate; Carlos M De Castro; H Joachim Deeg; Amy E DeZern; Amir T Fathi; Olga Frankfurt; Karin Gaensler; Guillermo Garcia-Manero; Elizabeth A Griffiths; David Head; Virginia Klimek; Rami Komrokji; Lisa A Kujawski; Lori J Maness; Margaret R O'Donnell; Daniel A Pollyea; Bart Scott; Paul J Shami; Brady L Stein; Peter Westervelt; Benton Wheeler; Dorothy A Shead; Courtney Smith Journal: J Natl Compr Canc Netw Date: 2015-03 Impact factor: 11.908
Authors: S L Shirley Ding; S N Leow; R Munisvaradass; E H Koh; M L C Bastion; K Y Then; S Kumar; P L Mok Journal: Eye (Lond) Date: 2016-06-10 Impact factor: 3.775
Authors: Pilar Ma Samper Ots; Concepción López Carrizosa; Aurora Rodríguez Pérez; Juan de Dios Saez Garrido; José Ma Delgado Pérez Journal: Clin Med Oncol Date: 2008-05-19